S Rauschert1, K Raubenheimer2, P E Melton3,4,5, R C Huang6. 1. Telethon Kids Institute, University of Western Australia, Nedlands, Perth, Western Australia. Sebastian.Rauschert@telethonkids.org.au. 2. School of Medicine, Notre Dame University, Fremantle, Western Australia. 3. Centre for Genetic Origins of Health and Disease, The University of Western Australia and Curtin University, Perth, Western Australia. 4. School of Pharmacy and Biomedical Sciences, Curtin University, Bentley, Western Australia. 5. Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia. 6. Telethon Kids Institute, University of Western Australia, Nedlands, Perth, Western Australia.
Abstract
BACKGROUND: Machine learning is a sub-field of artificial intelligence, which utilises large data sets to make predictions for future events. Although most algorithms used in machine learning were developed as far back as the 1950s, the advent of big data in combination with dramatically increased computing power has spurred renewed interest in this technology over the last two decades. MAIN BODY: Within the medical field, machine learning is promising in the development of assistive clinical tools for detection of e.g. cancers and prediction of disease. Recent advances in deep learning technologies, a sub-discipline of machine learning that requires less user input but more data and processing power, has provided even greater promise in assisting physicians to achieve accurate diagnoses. Within the fields of genetics and its sub-field epigenetics, both prime examples of complex data, machine learning methods are on the rise, as the field of personalised medicine is aiming for treatment of the individual based on their genetic and epigenetic profiles. CONCLUSION: We now have an ever-growing number of reported epigenetic alterations in disease, and this offers a chance to increase sensitivity and specificity of future diagnostics and therapies. Currently, there are limited studies using machine learning applied to epigenetics. They pertain to a wide variety of disease states and have used mostly supervised machine learning methods.
BACKGROUND: Machine learning is a sub-field of artificial intelligence, which utilises large data sets to make predictions for future events. Although most algorithms used in machine learning were developed as far back as the 1950s, the advent of big data in combination with dramatically increased computing power has spurred renewed interest in this technology over the last two decades. MAIN BODY: Within the medical field, machine learning is promising in the development of assistive clinical tools for detection of e.g. cancers and prediction of disease. Recent advances in deep learning technologies, a sub-discipline of machine learning that requires less user input but more data and processing power, has provided even greater promise in assisting physicians to achieve accurate diagnoses. Within the fields of genetics and its sub-field epigenetics, both prime examples of complex data, machine learning methods are on the rise, as the field of personalised medicine is aiming for treatment of the individual based on their genetic and epigenetic profiles. CONCLUSION: We now have an ever-growing number of reported epigenetic alterations in disease, and this offers a chance to increase sensitivity and specificity of future diagnostics and therapies. Currently, there are limited studies using machine learning applied to epigenetics. They pertain to a wide variety of disease states and have used mostly supervised machine learning methods.
Authors: Joshua J Levy; Youdinghuan Chen; Nasim Azizgolshani; Curtis L Petersen; Alexander J Titus; Erika L Moen; Louis J Vaickus; Lucas A Salas; Brock C Christensen Journal: NPJ Syst Biol Appl Date: 2021-08-20